Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluticasone Furoate

FDA-approved product (spray, metered, nasal), marketed as Arnuity Ellipta, Flonase Sensimist Allergy Relief.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fluticasone Furoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Allergic rhinitis
  • Asthma
  • Chronic obstructive pulmonary disease
  • Nasal congestion
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids; Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluticasone Furoate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluticasone Furoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation

    NCT07192016 · start 2026-04-24

    Registered record
    Registry ID
    NCT07192016
    Conditions
    Chronic Obstructive Pulmonary Disease (COPD)
    Interventions
    fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-04-24
    Completion
    2027-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease (COPD)
    Interventionfluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg
    PhasePhase 4
    Registry statusRecruiting

  • Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE

    NCT06705387 · start 2024-12-23

    Registered record
    Registry ID
    NCT06705387
    Conditions
    Eosinophilic Esophagitis
    Interventions
    Dupilumab; Fluticasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-12-23
    Completion
    2027-03
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEosinophilic Esophagitis
    InterventionDupilumab; Fluticasone
    PhasePhase 2
    Registry statusRecruiting

  • Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

    NCT02630121 · start 2023-04-01

    Registered record
    Registry ID
    NCT02630121
    Conditions
    Sleep Apnea; Chronic Nasal Congestion
    Interventions
    Oxymetazoline Hydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-04-01
    Completion
    2026-04
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Apnea; Chronic Nasal Congestion
    InterventionOxymetazoline Hydrochloride; Placebo
    PhasePhase 4
    Registry statusRecruiting

  • Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation

    NCT04655508 · start 2021-05-21

    Registered record
    Registry ID
    NCT04655508
    Conditions
    Stem Cell Transplant Complications; Respiratory Disease; Bronchiolitis Obliterans
    Interventions
    Seretide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-05-21
    Completion
    2023-09-27
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStem Cell Transplant Complications; Respiratory Disease; Bronchiolitis Obliterans
    InterventionSeretide; Placebo
    PhasePhase 3
    Registry statusTerminated

  • A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50

    NCT03562923 · start 2018-10

    Registered record
    Registry ID
    NCT03562923
    Conditions
    Asthma
    Interventions
    Test Product; Reference Product; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2018-10
    Completion
    2019-06
    Enrolment
    1,204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionTest Product; Reference Product; Placebo
    PhasePhase 3
    Registry statusUnknown

  • A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

    NCT03478696 · start 2018-06-25

    Registered record
    Registry ID
    NCT03478696
    Conditions
    Pulmonary Disease, Chronic Obstructive
    Interventions
    budesonide/formoterol; albuterol/salbutamol; FF/UMEC/VI; Placebo to match budesonide/formoterol; tiotropium; Placebo to match FF/UMEC/VI; placebo to match tiotropium; ELLIPTA; MDI; HandiHaler
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-06-25
    Completion
    2019-03-18
    Enrolment
    732

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive
    Interventionbudesonide/formoterol; albuterol/salbutamol; FF/UMEC/VI; Placebo to match budesonide/formoterol +6 more
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.

    NCT05342558 · start 2017-09-19

    Registered record
    Registry ID
    NCT05342558
    Conditions
    COPD
    Interventions
    Fluticasone Furoate/Vilanterol 100/25 mcgs; Umeclidinium/Vilanterol 62.5/25 mcgs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-09-19
    Completion
    2021-02-01
    Enrolment
    133

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD
    InterventionFluticasone Furoate/Vilanterol 100/25 mcgs; Umeclidinium/Vilanterol 62.5/25 mcgs
    PhasePhase 4
    Registry statusCompleted

  • The Causal Relation of Nasal Nitric Oxide Levels to the Severity of Chronic Rhinosinusitis and Its Inflammatory Phenotype

    NCT04171167 · start 2017-04-04

    Registered record
    Registry ID
    NCT04171167
    Conditions
    Chronic Rhinosinusitis (Diagnosis)
    Interventions
    Fluticasone Propionate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2017-04-04
    Completion
    2026-12
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Rhinosinusitis (Diagnosis)
    InterventionFluticasone Propionate
    PhaseNot applicable
    Registry statusActive not recruiting

  • SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study

    NCT02778867 · start 2016-05-20

    Registered record
    Registry ID
    NCT02778867
    Conditions
    Eosinophilic Gastrointestinal Disorders (EGIDs); Eosinophilic Esophagitis (EoE)
    Interventions
    1 Food Elimination Diet Therapy; 6 Food Elimination Diet Therapy; 6 Food Elimination Diet (after 1FED failure); Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2016-05-20
    Completion
    2019-05-29
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEosinophilic Gastrointestinal Disorders (EGIDs); Eosinophilic Esophagitis (EoE)
    Intervention1 Food Elimination Diet Therapy; 6 Food Elimination Diet Therapy; 6 Food Elimination Diet (after 1FED failure); Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)

    NCT02826343 · start 2016-05-01

    Registered record
    Registry ID
    NCT02826343
    Conditions
    Pulmonary Disease, Chronic Obstructive
    Interventions
    Xenon129 MRI imaging; Gadolinium MRI; Advair (250mcg/50mcg) one puff twice a day
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2016-05-01
    Completion
    2018-06-15
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive
    InterventionXenon129 MRI imaging; Gadolinium MRI; Advair (250mcg/50mcg) one puff twice a day
    PhaseEarly phase 1
    Registry statusCompleted

  • Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma

    NCT02571777 · start 2015-12-08

    Registered record
    Registry ID
    NCT02571777
    Conditions
    Asthma
    Interventions
    QVM149 150/50/160; QVM149 150/50/80; QMF149 150/320; QMF149 150/160; salmeterol/fluticasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-12-08
    Completion
    2019-06-14
    Enrolment
    3,092

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionQVM149 150/50/160; QVM149 150/50/80; QMF149 150/320; QMF149 150/160 +1 more
    PhasePhase 3
    Registry statusCompleted

  • Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

    NCT02467452 · start 2015-05

    Registered record
    Registry ID
    NCT02467452
    Conditions
    Chronic Obstructive Pulmonary Disease
    Interventions
    BDP/FF/GB; FlF/VI + Tiotropium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-05
    Completion
    2017-01
    Enrolment
    1,479

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease
    InterventionBDP/FF/GB; FlF/VI + Tiotropium
    PhasePhase 3
    Registry statusCompleted

  • Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray Irradiation

    NCT03673384 · start 2015-03-02

    Registered record
    Registry ID
    NCT03673384
    Conditions
    Allergic Rhinitis
    Interventions
    infrared-C ray irradiation; eye mask; Xyzal Oral Product; Fluticasone Furoate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-03-02
    Completion
    2017-07-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis
    Interventioninfrared-C ray irradiation; eye mask; Xyzal Oral Product; Fluticasone Furoate
    PhaseNot applicable
    Registry statusCompleted

  • ICS/LABA Combination With Integrated Dose Counter and Smartphone APP to Improve Asthma Control

    NCT02556073 · start 2014-08

    Registered record
    Registry ID
    NCT02556073
    Conditions
    Asthma
    Interventions
    Smartphone action; usual care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2014-08
    Completion
    2016-12
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionSmartphone action; usual care
    PhaseNot applicable
    Registry statusUnknown

  • Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

    NCT02105974 · start 2014-04-07

    Registered record
    Registry ID
    NCT02105974
    Conditions
    Pulmonary Disease, Chronic Obstructive
    Interventions
    Fluticasone Furoate/Vilanterol; Vilanterol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-04-07
    Completion
    2015-07-08
    Enrolment
    1,621

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive
    InterventionFluticasone Furoate/Vilanterol; Vilanterol
    PhasePhase 3
    Registry statusCompleted